TABLE 1.

A summary of new systemic drug therapies for psoriasis

DRUG	CURRENT STATUS AND OBSERVATIONS	COMMENTS
Certolizumab-Pegol	Developed for treating Crohn’s disease
Ustekinumab	Antagonizes IL-23 by targeting the p19 subunit (not shared)	Pure IL-23 antagonist; adverse events include risk of serious infection
Guselkumab	Phase 2 dose-ranging studies resulted in comparisons to adalimumab
Tidrakizumab	Phase 2 dose-ranging studied, good PASI-90 scores at 12 weeks. Antagonizes IL-23 by targeting p19 subunit	Well-tolerated
Boehringer-Ingelheim 655066	Novel monoclonal antibody, phase 2 proof-ofconcept study with 58% achieving PASI-90 and remaining clear at 66 weeks	Subcutaneous injection, may need dosing only every four months
Secukinumab, ixekizumab, and brodalumab	IL-17 antagonists	Secukinumab approved in U.S. for psoriasis in May 2015